Search Videos by Topic or Participant
Browse by Series:

Strategies for Delivering Maintenance Therapy in NSCLC

Insight From: Primo N. Lara, Jr, MD, UC Davis; Benjamin P. Levy, MD Mount Sinai; Jyoti D. Patel, MD Northwestern 
Published: Thursday, Jan 01, 2015
For High-Definition, Click
Following induction therapy, patients with NSCLC may receive maintenance therapy. For patients with nonsquamous histology, following induction therapy with carboplatin and pemetrexed, Jyoti D. Patel, MD, considers maintenance therapy with pemetrexed.

There are 2 strategies for delivering maintenance therapy, notes Benjamin P. Levy, MD: continuation maintenance and switch maintenance. With the continuation strategy, after completing induction therapy, patients discontinue the platinating agent and continue to receive the same non-platinating agent that was used in the induction regimen. With the switch strategy, after induction therapy, patients receive a different agent during maintenance therapy. To date, the only cytotoxic drug approved for maintenance therapy is pemetrexed, comments Levy.

Maintenance chemotherapy may be given immediately after 4 cycles of induction therapy or after a break from treatment. Levy remarks that in his practice, he generally gives maintenance chemotherapy immediately after induction therapy.  It is important to discuss maintenance chemotherapy at the beginning of treatment so that patients are aware that they may continue receiving chemotherapy even if their scans show stable disease, adds Levy.
Slider Left
Slider Right
For High-Definition, Click
Following induction therapy, patients with NSCLC may receive maintenance therapy. For patients with nonsquamous histology, following induction therapy with carboplatin and pemetrexed, Jyoti D. Patel, MD, considers maintenance therapy with pemetrexed.

There are 2 strategies for delivering maintenance therapy, notes Benjamin P. Levy, MD: continuation maintenance and switch maintenance. With the continuation strategy, after completing induction therapy, patients discontinue the platinating agent and continue to receive the same non-platinating agent that was used in the induction regimen. With the switch strategy, after induction therapy, patients receive a different agent during maintenance therapy. To date, the only cytotoxic drug approved for maintenance therapy is pemetrexed, comments Levy.

Maintenance chemotherapy may be given immediately after 4 cycles of induction therapy or after a break from treatment. Levy remarks that in his practice, he generally gives maintenance chemotherapy immediately after induction therapy.  It is important to discuss maintenance chemotherapy at the beginning of treatment so that patients are aware that they may continue receiving chemotherapy even if their scans show stable disease, adds Levy.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x